New insider activity at Insmed ( (INSM) ) has taken place on May 16, 2025.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Insmed’s top executives have recently made significant stock sales, collectively amounting to millions. CFO Sara Bonstein sold 10,504 shares for $708,681. CLO Michael Alexander Smith parted with 4,816 shares, netting $325,673. Chair and CEO William Lewis’s transaction involved 21,213 shares, yielding $1,415,572. CMO Martina M.D. Flammer sold 10,152 shares for $684,570. COO Roger Adsett’s sale of 9,407 shares brought in $633,653. Lastly, Chief People Strategy Officer Orlov Nicole Schaeffer sold 6,235 shares, amounting to $420,076.
Recent Updates on INSM stock
Insmed has seen significant developments recently, with Jefferies initiating coverage with a positive outlook due to the company’s ‘first-in-disease status’ and strong clinical profile, particularly for its bronchiectasis treatment, brensocatib, which is anticipated to be a ‘potential megablockbuster.’ The company’s Q1 2025 earnings report highlighted a 23% year-over-year revenue growth for ARIKAYCE, driven by strong performances in the U.S., Japan, and Europe, and a robust cash position of $1.2 billion. The positive sentiment is further supported by the publication of Phase 3 ASPEN trial results for brensocatib in the New England Journal of Medicine, indicating smooth regulatory progress in the U.S., Europe, and the U.K. Despite a net loss, Insmed remains optimistic about its growth prospects, focusing on expanding ARIKAYCE’s commercialization and preparing for brensocatib’s potential launch. However, challenges such as regulatory uncertainties and market access issues, including pricing and reimbursement strategies, remain. UBS slightly lowered its price target due to these potential challenges, but the overall outlook remains positive with expectations of continued revenue growth and successful regulatory outcomes.
Spark’s Take on INSM Stock
According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.
Insmed’s stock score reflects the company’s challenging financial performance, with consistent losses and high leverage posing significant risks. Technical analysis indicates bearish momentum, while the negative P/E ratio suggests caution in valuation. Positives from the earnings call, including strong cash reserves and progress in clinical programs, along with favorable corporate events, provide some optimism but are overshadowed by financial and market challenges.
To see Spark’s full report on INSM stock, click here.
More about Insmed
YTD Price Performance: -6.20%
Average Trading Volume: 2,272,581
Technical Sentiment Signal: Buy
Current Market Cap: $11.97B